Header links
Intranet
Donate now
image/svg+xml Map
Contact us

General finder

What are you looking for?

Write the name, title or any keyword related to what you are looking for and select which content category it belongs to.

Professionals

Eva María Pastor Arroyo

Professionals

Sandra León Cobos

Professionals

Mercedes López González

Professionals

Andrea Casal Pardo

Professionals

Alberto Real Martinez
Year
2025
Títol Complet
Service provider of a comprehensive tool for genomic analysis and online biological data interpretation of Pediatric Tumors for the Childhood Cancer and Hematologic Diseases Group of the Fundació Hospital Universitari Vall Hebron - Institut de Recerca (VHIR)
Expedient
GENOMIC ANALYSIS OF PEDIATRIC TUMORS
Codi
24985454
Data publicació
Documentos (enllaços)
ANUNCI DE LICITACIÓ
PLEC DE CLÀUSULES ADMINISTRATIVES PARTICULARS
ANNEX 1 PCAP
PLEC DE PRESCRIPCIONS TÈCNIQUES
PRINCIPALS PUNTS SOBRE DIGITAL
DEUC
DEUC FORMAT XML
INSTRUCCIONS PER EMPLENAR EL DEUC
ACORD DE NECESSITAT
CERTIFICAT D'EXISTÈNCIA DE CRÈDIT
RESOLUCIÓ APROVACIÓ DE L'EXPEDIENT
RESOLUCIÓ DESIGNACIÓ MESA DE CONTRACTACIÓ
RESOLUTION MODIFY OPENING OF ENVELOPE NO. 1
RESOLUTION 2 MODIFY OPENING OF ENVELOPE NO. 1

AFFIRM: A Randomized, double-blind, placebo-controlled, study to evaluate the effect of Seladelpar on clinical outcomes in patients with primary biliary cholangitis (PBC) and compensated cirrhosis.

Open
  • Protocol code: CB8025-41837
  • EudraCT code: _
  • Research group: Liver Diseases
  • Service: Hepatology
  • Principal investigator:  Villagrasa Vilella, Ares Aurora
  • Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
  • Phase: Fase III

A 2-Part, Randomized, Double-Blind, Placebo-Controlled Study in Participants with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping with an Initial Multiple Ascending Dose Part A to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ENTR-601-45, Followed by Part B to Evaluate the Safety and Efficacy of ENTR-601-45 (ELEVATE-45)

Open

Estudio de fase 1b que combina dinutuximab beta (DB) con regímenes de quimioterapia de inducción en pacientes con neuroblastoma de alto riesgo de reciente diagnóstico.

Open
  • Protocol code: SIOPEN-PILOT01
  • EudraCT code: No aplica
  • Research group: Childhood Cancer and Blood Disorders
  • Service: Pediatric Oncohematology
  • Principal investigator:  Moreno Martín-Retortillo, Lucas
  • Pathology: Tumors
  • Phase: Fase I

A phase 1 open-label trial to evaluate the safety, tolerability, pharmacodynamics, pharmacokinetics, and immunogenicity of subcutaneous VIS171 in participants with autoimmune disease(s).

Open
  • Protocol code: VIS171-103
  • EudraCT code: _
  • Research group: Nephrology and kidney transplantation
  • Service: Nephrology
  • Principal investigator:  Sans Atxer, Laia
  • Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
  • Phase: Fase I

Estudio aleatorizado, doble ciego para evaluar la eficacia y laseguridad de CAL101 en pacientes con fibrosis pulmonar idiopática.

Open
  • Protocol code: CAL-101-201
  • EudraCT code: No aplica
  • Research group: Pneumology
  • Service: Pneumology
  • Principal investigator:  Villar Gomez, Ana
  • Pathology: Malalties del sistema respiratori
  • Phase: Fase II

Estudio de fase 3, multicéntrico y abierto para evaluar la farmacocinética, la farmacodinamia, la eficacia y la seguridad de Ravulizumab en participantes pediátricos (de 2 a <18 años de edad) con Nefropatía primaria por Inmunoglobulina A (NIgA)

Open
  • Protocol code: ALXN1210-IgAN-325
  • EudraCT code: No aplica
  • Research group: Kidney Physiopathology
  • Service: Pediatric Nephrology
  • Principal investigator:  Ariceta Iraola, Gema
  • Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
  • Phase: Fase III
  • Status: Recruiting volunteers

A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO ASSESS EFFICACY AND SAFETY OF OMECAMTIV MECARBIL IN PATIENTS WITH SYMPTOMATIC HEART FAILURE WITH SEVERELY REDUCED EJECTION FRACTION

Open
  • Protocol code: CY 1033
  • EudraCT code: No aplica
  • Research group: Cardiovascular Diseases
  • Service: Cardiology
  • Principal investigator:  Méndez Fernández, Ana Belén
  • Pathology: Malalties del sistema circulatori
  • Phase: Fase III
  • Status: Recruiting volunteers

Estudio de fase 2, aleatorizado, abierto y controlado para evaluar la eficacia y la seguridad de rapcabtagene autoleucel frente a un comparador en participantes con miopatías inflamatorias idiopáticas refractarias graves

Open
  • Protocol code: CYTB323L12201
  • EudraCT code: No aplica
  • Research group: Systemic Diseases
  • Service: Internal Medicine
  • Principal investigator:  Selva O'Callaghan, Albert
  • Pathology: Malalties del sistema osteomuscular i del teixit connectiu
  • Phase: Fase II

Open-label, single-arm, non-controlled trial to evaluate the safety and tolerability of treprostinil sodium in children below the age of 18 years with pulmonary arterial hypertension (PAH)]

Open
  • Protocol code: TREPaed
  • EudraCT code: No aplica
  • Research group: Growth and Development
  • Service: General Pediatrics and Specialties
  • Principal investigator:  Moreno Galdó, Antonio
  • Pathology: Malalties del sistema respiratori
  • Phase: Fase III
  • Status: Recruiting volunteers

An interventional efficacy and safety phase 3, double-blind, 2-arm study to investigate IV followed by oral fosmanogenix compared with IV caspofungin follow by oral fluconazole in adult participants with candidemia and/or invasive cansidiasis

Open
  • Protocol code: FMGX-CS-301
  • EudraCT code: No aplica
  • Research group: Shock, Organ Dysfunction and Resuscitation
  • Service: RTA ICU
  • Principal investigator:  Ferrer Roca, Ricard
  • Pathology: Tumors
  • Phase: Fase III
  • Status: Recruiting volunteers

Eficacia de la colchicina en prevención secundaria de eventos vasculares y progresión renal en pacientes con enfermedad renal crónica moderada

Open
  • Protocol code: FIBHGM-ECNC002-colchiren
  • EudraCT code: _
  • Research group: Nephrology and kidney transplantation
  • Service: Nephrology
  • Principal investigator:  Bermejo Garcia, Sheila
  • Pathology: Malalties del sistema genitourinari
  • Phase: Fase III
  • Status: Recruiting volunteers

Estudio aleatorizado de fase II, doble ciego y controlado con placebo para evaluar la eficacia, la seguridad y la tolerabilidad de RO7204239 en combinación con tirzepatida en participantes con obesidad o sobrepeso y con al menos una comorbilidad relacionada con el peso

Open
  • Protocol code: BC45538
  • EudraCT code: No aplica
  • Research group: Diabetes and Metabolism
  • Service: Endocrinology
  • Principal investigator:  Ciudin Mihai, Andreea
  • Pathology: Malalties endocrines, nutricionals i metabòliques
  • Phase: Fase II

A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 3 Trial Evaluating the Efficacy and Safety of Felzartamab in Kidney Transplant Recipients with Late Antibody-Mediated Rejection (AMR) (TRANSCEND)

Open
  • Protocol code: 299AR301
  • EudraCT code: No aplica
  • Research group: Nephrology and kidney transplantation
  • Service: Nephrology
  • Principal investigator:  Bestard Matamoros, Oriol
  • Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
  • Phase: Fase III
  • Status: Recruiting volunteers

Optimizing Reperfusion to Improve Outcomes and Neurologic Function (ORION): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Phase 2/3 Study to Evaluate the Efficacy and Safety of JX10 in Acute Ischemic Stroke with Late Presentations

Open
  • Protocol code: JX10002
  • EudraCT code: No aplica
  • Research group: Stroke Research
  • Service: Neurology
  • Principal investigator:  Molina Cateriano, Carlos
  • Pathology: Malalties del sistema circulatori
  • Phase: Fase III